Astellas Pharma to exclusively commercialize isavuconazole in the U.S. and Canada

NewsGuard 100/100 Score

Astellas Pharma Inc. (Tokyo:4503, "Astellas") announced today that the company has amended the License, Co-Development and Co-Promotion Agreement on isavuconazole under co-development with Basilea Pharmaceutica Ltd. ("Basilea"). Based on this amendment, the territories subject to the License Agreement have been changed to reflect that Astellas will be responsible for all regulatory filings and will exclusively commercialize and assume full responsibility for manufacturing isavuconazole in the U.S. and Canada.

Basilea assumes full rights to isavuconazole in the rest of the world in return for waiving its right to co-promote the product in the U.S. and Canada. The original agreement was executed in February 2010. Under the amended agreement, the submission of the New Drug Application (NDA) and potential approval in the U.S. will continue to be subject to the payment of a development milestone by Astellas. In addition, the conditions regarding sales milestone payments have been changed. Accordingly, the total amount of the development and sales milestones that Astellas is subject to paying Basilea is CHF 374 million.

Astellas will continue its collaborative relationship with Basilea on the development of isavuconazole to provide a new therapeutic option for the treatment of serious fungal infections to patients in the U.S. and Canada.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.